Latest News & Features
Refine Search
Americas
As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look. 1 May 2011
Biotechnology
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains. 1 May 2011
Americas
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007. 1 May 2011
Big Pharma
Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled. 1 May 2011
Americas
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs. 1 May 2011
Europe
There is a contradiction at the heart of product definition in Swedish supplementary protection certificates, says Hampus Rystedt. 1 May 2010
Biotechnology
A growing number of biotechnology inventions relate to peptides, oligonucleotides and other small molecules that could be used in therapeutic applications. Caroline Pallard explains the challenges of patenting such inventions. 1 May 2010
Europe
Following the implementation of EU Directive 2004/48/EC on the enforcement of IP rights under French patent law in 2007 and the publication of the corresponding implementing rules in 2008, the criteria adopted by the French courts to grant preliminary injunctions have also changed. 1 May 2010
Americas
A recent US district court ruling could significantly affect companies that patent genes and threaten the health of an entire industry. LSIPR investigates. 1 May 2010
Americas
Two pharmaceutical cases highlight recent developments in Canadian patent law relating to duty of candour during patent prosecution and patent claim construction, says Katie Wang. 1 May 2010